Advertisement

Effectiveness of low-dose riboflavin as a prophylactic agent in pediatric migraine

      Abstract

      Background

      Riboflavin may prevent migraine episodes; however, there is limited evidence of its effectiveness in pediatric populations. This study investigated the effectiveness of riboflavin and clinical predictors of response in children with migraines.

      Methods

      We retrospectively reviewed data from 68 Japanese children with migraines, of whom 52 also exhibited another type of headache. Patients received 10 or 40 mg/day of riboflavin. We evaluated the average migraine frequency per month as a baseline and after 3 months of riboflavin therapy to determine the effectiveness and clinical predictors of response.

      Results

      The frequency of migraine episodes was significantly lower at 3 months than at baseline (median, [interquartile range], 5.2 (3–7) vs. 4.0 (2–5); p < 0.01). Twenty-five patients (36.7%) showed 50% or greater reduction in episode frequency (responders), while 18 (26.5%) showed a 25%–50% reduction. We compared responders (n = 25) and non-responders (n = 43) and found no significant differences in sex, familial history, riboflavin dose, migraine type (i.e., presence or absence of aura), age at headache onset, or age at consultation. However, non-responders were more likely to have co-morbid non-migraine headaches (odds ratio, 4.11; 95% confidence interval [CI], 1.27–13.33; p = 0.02); this variable was also significant in a multivariate analysis (adjusted odds ratio, 3.8; 95% CI, 1.16–12.6; p = 0.03). Of the co-morbid headache types, only tension headaches were significant (odds ratio, 0.176; 95% CI, 0.04–0.73; p = 0.013). No adverse effects of riboflavin were identified.

      Conclusions

      Low-dose riboflavin is safe and modestly effective for migraines in children. It may be especially beneficial for children without other co-morbid headache types.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Powers S.W.
        • Patton S.R.
        • Hommel K.A.
        • Hershey A.D.
        Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses.
        Pediatrics. 2003; 112: e1-e5
        • Powers S.W.
        • Hershey A.D.
        • Coffey C.S.
        • Chamberlin L.A.
        • Ecklund D.J.D.
        • Sullivan S.M.
        • et al.
        The Childhood and Adolescent Migraine Prevention (CHAMP) study: a report on baseline characteristics of participants.
        Headache. 2016; 56: 859-870
        • Silberstein S.D.
        Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
        Neurology. 2000; 55: 754-762
        • Lewis D.
        • Ashwal S.
        • Hershey A.
        • Hirtz D.
        • Yonker M.
        • Silberstein S.
        Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.
        Neurology. 2004; 63: 2215-2224
        • Powers S.W.
        • Coffey C.S.
        • Chamberlin L.A.
        • Ecklund D.J.
        • Klingner E.A.
        • Yankey J.W.
        • et al.
        Trial of amitriptyline, topiramate, and placebo for pediatric migraine.
        N Engl J Med. 2017; 376: 115-124
        • Patterson-Gentile C.
        • Szperka C.L.
        The changing landscape of pediatric migraine therapy: a review.
        JAMA Neurol. 2018; 75: 881-887
        • Orr S.L.
        The evidence for the role of nutraceuticals in the management of pediatric migraine: a review.
        Curr Pain Headache Rep. 2018; 22: 37
        • Schoenen J.
        • Lenaerts M.
        • Bastings E.
        High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study.
        Cephalalgia. 1994; 14: 328-329
        • Schoenen J.
        • Jacquy J.
        • Lenaerts M.
        Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.
        Neurology. 1998; 50: 466-470
        • Rahimdel A.
        • Zeinali A.
        • Yazdian-Anari P.
        • Hajizadeh R.
        • Arefnia E.
        Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial.
        Electron Physician. 2015; 7: 1344-1348
        • Boehnke C.
        • Reuter U.
        • Flach U.
        • Schuh-Hofer S.
        • Einhaupl K.M.
        • Arnold G.
        High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre.
        Eur J Neurol. 2004; 11: 475-477
        • Reyngoudt H.
        • Paemeleire K.
        • Descamps B.
        • De Deene Y.
        • Achten E.
        31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients.
        Cephalalgia. 2011; 31: 1243-1253
        • Barbiroli B.
        • Montagna P.
        • Cortelli P.
        • Funicello R.
        • Iotti S.
        • Monari L.
        • et al.
        Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura.
        Neurology. 1992; 42: 1209-1214
        • Younis S.
        • Hougaard A.
        • Vestergaard M.B.
        • Larsson H.B.W.
        • Ashina M.
        Migraine and magnetic resonance spectroscopy: a systematic review.
        Curr Opin Neurol. 2017; 30: 246-262
        • Taylor F.R.
        Nutraceuticals and headache: the biological basis.
        Headache. 2011; 51: 484-501
        • Marashly E.T.
        • Bohlega S.A.
        Riboflavin has neuroprotective potential: focus on Parkinson's disease and migraine.
        Front Neurol. 2017; 8: 333
        • Athaillah A.
        • Dimyati Y.
        • Saing J.H.
        • Saing B.
        • Hakimi H.
        • Lelo A.
        Riboflavin as migraine prophylaxis in adolescents.
        Paediatr Indones. 2012; 52: 132-137
        • Talebian A.
        • Soltani B.
        • Banafshe H.R.
        • Moosavi G.A.
        • Talebian M.
        • Soltani S.
        Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial.
        Electron Physician. 2018; 10: 6279-6285
        • MacLennan S.C.
        • Wade F.M.
        • Forrest K.M.
        • Ratanayake P.D.
        • Fagan E.
        • Antony J.
        High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial.
        J Child Neurol. 2008; 23: 1300-1304
        • Bruijn J.
        • Duivenvoorden H.
        • Passchier J.
        • Locher H.
        • Dijkstra N.
        • Arts W.F.
        Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial.
        Cephalalgia. 2010; 30: 1426-1434
      1. Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

        • Condo M.
        • Posar A.
        • Arbizzani A.
        • Parmeggiani A.
        Riboflavin prophylaxis in pediatric and adolescent migraine.
        J Headache Pain. 2009; 10: 361-365
        • Nambiar N.J.
        • Aiyappa C.
        • Srinivasa S.
        Oral riboflavin versus oral propranolol in migraine prophylaxis: an open label randomized controlled trial.
        Neurol Asia. 2011; 16: 223-229
        • Maizels M.
        • Blumenfeld A.
        • Burchette R.
        A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.
        Headache. 2004; 44: 885-890
        • Macedo A.
        • Banos J.E.
        • Farre M.
        Placebo response in the prophylaxis of migraine: a meta-analysis.
        Eur J Pain. 2008; 12: 68-75
        • Zempleni J.
        • Galloway J.R.
        • McCormick D.B.
        Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans.
        Am J Clin Nutr. 1996; 63: 54-66
      2. Institute of Medicine Committee on Use of Dietary Reference Intakes in Nutrition L. Dietary Reference Intakes: Guiding Principles for Nutrition Labeling and Fortification. Dietary Reference Intakes: Guiding Principles for Nutrition Labeling and Fortification. Washington (DC): National Academies Press (US) Copyright 2003 by the National Academy of Sciences. All rights reserved.; 2003.

        • Pinto J.T.
        • Zempleni J.
        Riboflavin.
        Adv Nutr. 2016; 7: 973-975
        • Lewis D.W.
        • Winner P.
        • Wasiewski W.
        The placebo responder rate in children and adolescents.
        Headache. 2005; 45: 232-239
        • Lewis D.
        • Winner P.
        • Saper J.
        • Ness S.
        • Polverejan E.
        • Wang S.
        • et al.
        Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age.
        Pediatrics. 2009; 123: 924-934